Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by SeaOfSandon Nov 07, 2019 4:21am
78 Views
Post# 30319261

RE:RE:ColonSentry Blood Test Positioning

RE:RE:ColonSentry Blood Test PositioningOK Johnny, I see what you did here. First provoking and then releasing the good DD :)

Copying my DD from ceo.ca:

I went a little bit through the miRNA papers.
Spoiler: ColonSentry or Aristotel papers use their own Gene specifications (ANXA3 CLEC4D ..)
in contrast to the (more) standarized miRNA world, which uses miR-xxx-y.
When you look at the 2018 paper A panel of three plasma microRNAs for colorectal cancer diagnosis
https://www.sciencedirect.com/science/article/abs/pii/S1877782118301784
it concludes:

We demonstrated that seven miRNAs may function as noninvasive biomarkers to detect CRC. The consistency check results showed good agreement between miRNAs and the golden standard paraffin pathology to diagnose CRC. In particular, the panel of three miRNAs (miR-144-3p, miR-425-5p, and miR-1260b) yielded an AUC of 0.954, with 93.8% sensitivity and 91.3% specificity, which demonstrated higher diagnostic performance compared with the single-factor index. Furthermore, miRNA target prediction and pathway enrichment analysis indicated that the dysregulated miRNAs in CRC are functionally involved in several key cancer-related pathways, such as axonal guidance, PI3K, and calcium signaling pathways. Thus, the plasma 3-miRNA panel may serve as a novel noninvasive biomarker for CRC diagnosis and may be related to CRC development. However, further studies are needed to highlight the theoretical strengths of this approach.

The ColonSentry 6-gene + comparison 1-gene panel papers from 2010
https://jeccr.biomedcentral.com/articles/10.1186/1756-9966-29-128
and 2009 https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.24910
disclose a similar methodology but are less bullish on the sensitivity and specificity results.
It should be looked at why this is, as both use miRNA gene panels.
However, note that the ColonSentry 70% efficacy cut-off line
targets 100% specificy in the 2010 paper figure 3!

It is possible that the very small difference observed might be due to sample size
and measurement accuracy etc.
Bottom line is, ColonSentry's science is real and this is being heavily researched today.
Bullboard Posts